Wash U Team Looks to Expand on Initial Success of Sequencing in Breast Cancer Clinical Trial

The Wash U researchers sequenced 50 tumor/normal breast cancer pairs in order to gain insight into the mechanisms that underlie resistance to aromatase inhibitor therapy. They plan to use the same approach in another trial that is studying trastuzumab plus chemotherapy in HER2-positive breast cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.